G6PD and Tumor Lysis Syndrome: The U.S. Food and Drug Administration (FDA) recommends testing for G6PD prior to treatment of tumor lysis syndrome with rasburicase, but the absence of a rapid G6PD test makes this recommendation difficult to follow [10].